Innaxon and AdipoGen Life Sciences Lipodisq novel lipid/polymer nanoparticles

Lipodisq novel lipid/polymer nanoparticles have been developed as mimics of naturally occurring high-density lipoproteins (HDL). The particles are in the size range of 11 to 40 nm in diameter, enabling enhanced penetration and diffusion into membranes. The nanodisc lipid particles are composed of a hydrophilic shell and hydrophobic core in which hydrophobic active agents can be carried and protected.

The size and shape of the chaperone molecule is a critical factor in Lipodisq formation and also defines the properties of the particle, ie, particle size and/or its biodegradability. Internal properties of the phospholipid membrane support the disposition and stabilisation of drug molecule candidates and preserve the native conformation of membrane-bound molecules. The resulting encapsulated actives are rendered water-soluble and optimised for intracellular penetration/delivery via endosomal uptake mechanisms.

Actives in Lipodisq are biosynthetic water-soluble nanodiscs prepared under SOPs using selected optimised lipid compositions for stable, high-loading capacity of encapsulated active ingredients, and retain the biological activity of the active compound with enhanced bioavailability. The solutions show a good safety profile and are suitable for in vitro and in vivo investigations.

Innaxon and AdipoGen Life Sciences offer a range of antiviral and immunomodulating compounds in Lipodisq formulations including ambroxol, curcumin, dexamethasone, melatonin, metformin, oxyresveratrol, resveratrol and umifenovir. The products are distributed in Australia and New Zealand by Sapphire Bioscience.